Amgen AMGN
NASDAQ AMGN
$382.47 -8.80 (-2.25%)
At close: Sep 10, 2026 · 4:00 PM EDT

Amgen (AMGN) Convertible Debt (2009 - 2010)

Amgen (AMGN) posted Convertible Debt of $2.2 billion for Q1 2010, down 51.22% on a QoQ basis from $4.5 billion in Q4 2009.

Analysis

Amgen (AMGN) Convertible Debt (2009 - 2010) Analysis & Trends

Amgen has reported Convertible Debt for 2 years, with the latest figure at $2.2 billion in Q1 2010.

  • On a quarterly basis, Convertible Debt changed N/A year-over-year to $2.2 billion in Q1 2010; TTM through Mar 2010 was $2.2 billion, a N/A change from a year earlier, with the FY2009 full-year figure at $4.5 billion, changed N/A from the prior year.
  • Convertible Debt was $2.2 billion for Q1 2010 at Amgen, down from $4.5 billion in the prior quarter.
  • The five-year high for Convertible Debt was $4.5 billion in Q4 2009, with the low at $2.2 billion in Q1 2010.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Insmed 27.67 Bn 26.51 Bn 358.27 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2010 2.20 Bn
Dec 31, 2009 4.51 Bn
Sep 30, 2009 4.45 Bn
Jun 30, 2009 4.38 Bn